OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company that entered public markets via a merger with Avista Public Acquisition Corp. II, a blank-check vehicle sponsored by Avista Capital Partners that held its IPO in 2021. Spun out of Ligand Pharmaceuticals, OmniAb operates an antibody discovery platform serving biopharmaceutical companies seeking to develop novel therapeutics. The Form 10-Q/A filed on January 12, 2022, represents an amended quarterly disclosure from the SPAC entity's pre-combination reporting period. The business combination subsequently closed, with the combined company trading on Nasdaq under the ticker OABI. Visit SpacDesk to sign up for full filing history, deal analytics, and real-time data on OABI and the broader SPAC market.